Dissemination of Strongyloides stercoralis in a patient with systemic lupus erythematosus after initiation of albendazole: a case report

Catherine J Hunter¹ , Mikael Petrosyan² and Morris Asch¹

¹Harbor UCLA Medical Center, W Carson Street, Department of Surgery, Torrance, CA 90502, USA

²University of Southern California, Keck School of Medicine, North State Street, Los Angeles, CA 90033, USA

author email corresponding author email

Journal of Medical Case Reports 2008, 2:156doi:10.1186/1752-1947-2-156


Published:	14 May 2008

Abstract

Introduction

Strongyloides stercoralis infection affects hundreds of millions of people worldwide. As immigration rates and international travel increase, so does the number of cases of strongyloidiasis in the United States. Although described both in immigrant and in immunosuppressed populations, hyperinfection and dissemination of S. stercoralis following the initiation of antiparasitic medication is a previously unreported phenomenon.

Case presentation

Here we describe the case of a 38-year-old immunocompromised woman with systemic lupus erythematosus, who developed disseminated disease following treatment with albendazole (400 mg every 12 hours). Notably the patient was receiving oral prednisone (10 mg once daily), azathioprine (50 mg twice daily), and hydroxychloroquine (400 mg daily) at the time of hospitalization. The patient was subsequently treated successfully with ivermectin (200 mcg/kg daily).

Conclusion

The reader should be aware that dissemination of S. stercoralis can occur even after the initiation of antiparasitic medication.